Treatment of acute myeloid leukemia with gefitinib: clinical trials recommended
Rachael Williams
This article has no abstract so we have provided the first paragraph of the full text.
Investigators have identified an FDA-approved drug that increases the degree of myeloid maturation in patients with mutations in differentiation-promoting transcription factors. They advocate gefitinib (Iressa®, AstraZeneca UK Limited, London, UK) as a promising alternative to cytotoxic agents for treating acute myeloid leukemia (AML).
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
An image worth a thousand lives?Nature Biotechnology News and Views (01 Jun 2004)
Gene expression as a drug discovery toolNature Genetics News and Views (01 Mar 2004)